A review written by Young, MD, Anderson Cancer Center, USA explained the application of PD-1 inhibitor immunotherapy in B-cell lymphoma. (Blood. Online version on November 8, 2017. doi: 10.1182 / blo...
A new study from McMaster University in Canada said that it has discovered a new treatment strategy for acute myeloid leukemia. By stimulating the production of fat cells in the bone marrow and adjust...
The Cleveland Clinic of the United States Eric D. His et al. Reported that the diagnosis of peripheral T cell lymphoma (PTCL) in the United States varies greatly, and often lacks important phenotypic ...
Acalabrutinib is a second-generation tyrosine kinase (BTK) inhibitor, a newer drug that can improve the survival of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).The researchers be...
Mature T-cell tumors, such as non-Hodgkin T-cell lymphoma, are highly invasive and drug-resistant, and patients often have a poor prognosis. Recently, "Nature" series of two articles published a new i...
Obesity not only runs counter to the aesthetics of people, but also causes many chronic diseases. Some studies have shown that body mass index (BMI) is related to the risk of cancer in certain parts (...
A study conducted at the Los Angeles Children ’s Hospital is providing the best treatment for a rare invasive leukemia called mixed phenotype acute leukemia (MPAL).This study (a 20-year quantitative...
Yesterday, the US FDA announced the approval of Seattle Genetics' antibody-drug conjugate Adcetris (brentuximab vedotin) in combination with chemotherapy for patients with previously treated stage III...
According to the results of a 5-year follow-up of the key PACE trial published in the Journal of Hematology, panatinib (Ponatinib, Iclusig) has maintained long-lasting in severely treated patients wit...
New Cleveland Clinic research shows for the first time that FDA-approved ibrutinib (ibrutinib) for lymphoma and leukemia may also help treat the most common and deadly brain tumors, and may one day be...